Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma

Cancer Investigation

Volumn 29, Issue 4, 2011, Pages 282-285

  Ayllon, Jorge ^a   Beuselinck, Benoit ^a   Morel, Alexandre ^a   Barrascout, Eduardo ^a   Medioni, Jacques ^a   Scotte, Florian ^a   Oudard, StéAphane ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Dose intensity; Long term efficacy; Renal cell carcinoma; Sunitinib; Surgical metastasis resection

Indexed keywords

ALPHA INTERFERON; ERYTHROPOIETIN; INTERLEUKIN 2; LEVOTHYROXINE; MORPHINE; SORAFENIB; SUNITINIB;

ADIPOSE TISSUE; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CASE REPORT; CONSTIPATION; DIARRHEA; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY VEIN; LOBECTOMY; LUMBAR SPINE; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MEDIASTINUM LYMPH NODE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; OLECRANON FRACTURE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN OCCLUSION;

ADMINISTRATION, ORAL; ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; AGED; ANGIOGENESIS INHIBITORS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEPHRECTOMY; OSTEOTOMY; PNEUMONECTOMY; PROTEIN KINASE INHIBITORS; PYRROLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953779522     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.568560     Document Type: Article

References (15)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. (Pubitemid 46089672)
2. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540. (Pubitemid 29368255)
3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
4. Houk BE, BelloCL, Poland B, Rosen LS, DemetriGD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/ pharmacodynamicmeta- analysis. Cancer Chemother Pharmacol. 2009 Dec 5. [Epub ahead of print]
5. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81-83.
6. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92:3531-3534. (Pubitemid 47435331)
7. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical modelsof human small cell lung cancer.MolCancer Ther 2003;2:471-478.
8. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070-4076. (Pubitemid 44536887)
9. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337. (Pubitemid 36109749)
10. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-766. (Pubitemid 38019277)
11. O'FarrellAM,Abrams TJ, YuenHA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605. (Pubitemid 36857948)
12. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-3590.
13. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)
14. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524. (Pubitemid 43854967)
15. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757-763.